

## **Pluvicto**

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	
Physician Office Telephone:	
<b>Referring Provider Info:</b> □ Same as Re	equesting Provider
Name:	NPI#:
Fax:	
<b>Rendering Provider Info:</b> □ Same as R	eferring Provider 🗆 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:
	t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines.
Required Demographic Information:	
Patient Weight:	kg
Patient Height:	CM

3. Is the patient currently receiving treatment with the requested medication? ☐ Yes ☐ No If No, skip to #6  4. Is there evidence of unacceptable toxicity or disease progression while on the current regimen? ☐ Yes ☐ No  5. How many doses of therapy has the patient received with the requested medication?  No further questions  6. Does the patient have metastatic castration-resistant prostate cancer? ☐ Yes ☐ No  7. Has the patient been treated with androgen receptor (AR) pathway inhibition (e.g., abiraterone) and taxane-based chemotherapy (e.g., docetaxel)? ☐ Yes ☐ No	<u>Cli</u> 1.	mical Criteria Questions:  What is the diagnosis?  Prostate cancer  Other
4. Is there evidence of unacceptable toxicity or disease progression while on the current regimen? □ Yes □ No  5. How many doses of therapy has the patient received with the requested medication?	2.	What is the ICD-10 code?
5. How many doses of therapy has the patient received with the requested medication?	3.	Is the patient currently receiving treatment with the requested medication? $\square$ Yes $\square$ No If No, skip to #6
	4.	Is there evidence of unacceptable toxicity or disease progression while on the current regimen? $\ \square$ Yes $\ \square$ No
<ul> <li>7. Has the patient been treated with androgen receptor (AR) pathway inhibition (e.g., abiraterone) and taxane-based chemotherapy (e.g., docetaxel)?</li></ul>	5.	
chemotherapy (e.g., docetaxel)?	6.	Does the patient have metastatic castration-resistant prostate cancer?
documentation of prostate-specific membrane antigen (PSMA) status.    PSMA positive	7.	
information is available for review if requested by CVS Caremark or the benefit plan sponsor.  X	8.	documentation of prostate-specific membrane antigen (PSMA) status.  □ PSMA positive □ PSMA negative
information is available for review if requested by CVS Caremark or the benefit plan sponsor.  X		
		escriber or Authorized Signature Date (mm/dd/vv)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please